Indrayani Biotech Limited (BOM:526445)
India · Delayed Price · Currency is INR 7.80
0.00 (0.00%)
At close: Aug 21, 2026
Indrayani Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,378 | 1,302 | 1,662 | 1,629 | 615.72 |
Other Revenue | 45.72 | - | - | 0.02 | 0.11 |
| 1,424 | 1,302 | 1,662 | 1,629 | 615.82 | |
Revenue Growth | 9.35% | -21.66% | 2.02% | 164.57% | 190.60% |
Cost of Revenue | 940.73 | 845.68 | 989.28 | 1,039 | 414.11 |
Gross Profit | 483.3 | 456.61 | 672.98 | 590.2 | 201.72 |
Selling, General & Admin | 141.62 | 221.23 | 258.36 | 252.87 | 107.75 |
Other Operating Expenses | 199.67 | 148.06 | 170.03 | 157.06 | 25.2 |
Operating Expenses | 384.3 | 402.97 | 466.39 | 443.41 | 139.54 |
Operating Income | 99.01 | 53.64 | 206.58 | 146.79 | 62.17 |
Interest Expense | -96.01 | -107.17 | -98.83 | -49.99 | -18.26 |
Interest & Investment Income | - | 6.33 | 1.57 | 26.09 | 1.14 |
Other Non Operating Income (Expenses) | -0 | -10.24 | 0.42 | 4.65 | -0.54 |
EBT Excluding Unusual Items | 3 | -57.44 | 109.74 | 127.54 | 44.52 |
Asset Writedown | - | - | - | -5 | - |
Other Unusual Items | - | - | - | 0.52 | - |
Pretax Income | 3 | -57.44 | 109.74 | 123.06 | 44.52 |
Income Tax Expense | -18.6 | 3.64 | 5.52 | 3.75 | 0.12 |
Earnings From Continuing Operations | 21.6 | -61.08 | 104.22 | 119.31 | 44.4 |
Minority Interest in Earnings | -17.9 | 45.51 | -40.58 | -31.94 | -0.46 |
Net Income | 3.7 | -15.57 | 63.65 | 87.37 | 43.93 |
Net Income to Common | 3.7 | -15.57 | 63.65 | 87.37 | 43.93 |
Net Income Growth | - | - | -27.15% | 98.87% | - |
Shares Outstanding (Basic) | 8 | 46 | 36 | 34 | 34 |
Shares Outstanding (Diluted) | 8 | 46 | 46 | 43 | 34 |
Shares Change | -83.06% | - | 4.74% | 27.02% | -3.86% |
EPS (Basic) | 0.48 | -0.34 | 1.75 | 2.55 | 1.28 |
EPS (Diluted) | 0.48 | -0.35 | 1.40 | 2.01 | 1.28 |
EPS Growth | - | - | -30.35% | 57.03% | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 237.49 | -81.17 | -466.56 | -53.4 | 29.22 |
Free Cash Flow Per Share | 30.78 | -1.78 | -10.25 | -1.23 | 0.85 |
Gross Margin | 33.94% | 35.06% | 40.49% | 36.22% | 32.76% |
Operating Margin | 6.95% | 4.12% | 12.43% | 9.01% | 10.10% |
Profit Margin | 0.26% | -1.20% | 3.83% | 5.36% | 7.13% |
Free Cash Flow Margin | 16.68% | -6.23% | -28.07% | -3.28% | 4.75% |
EBITDA | 142.02 | 87.32 | 244.64 | 180.26 | 68.77 |
EBITDA Margin | 9.97% | 6.71% | 14.72% | 11.06% | 11.17% |
D&A For EBITDA | 43.01 | 33.68 | 38.05 | 33.47 | 6.59 |
EBIT | 99.01 | 53.64 | 206.58 | 146.79 | 62.17 |
EBIT Margin | 6.95% | 4.12% | 12.43% | 9.01% | 10.10% |
Effective Tax Rate | - | - | 5.03% | 3.05% | 0.28% |
Revenue as Reported | 1,424 | 1,334 | 1,674 | 1,674 | 617.93 |
Advertising Expenses | - | 7.08 | 8.19 | 8.89 | 1.65 |